Associated Papers
Prevalence of HIV-1 Natural Polymorphisms and Integrase-Resistance-Associated Mutations in African Children.
Fofana DB et al.
Viruses, 2023
Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen.
Charpentier C et al.
The Journal of Antimicrobial Chemotherapy, 2018
Resistance to HIV Integrase Inhibitors: About R263K and E157Q Mutations.
Charpentier C et al.
Viruses, 2018
High prevalence of HIV-1 transmitted drug-resistance mutations from proviral DNA massively parallel sequencing data of therapy-naïve chronically infected Brazilian blood donors.
Pessôa R et al.
Plos One, 2017
Deep analysis of HIV-1 natural variability across HIV-1 variants at residues associated with integrase inhibitor (INI) resistance in INI-naive individuals.
Llácer Delicado T et al.
The Journal of Antimicrobial Chemotherapy, 2016
Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance.
Hardy I et al.
The Journal of Antimicrobial Chemotherapy, 2015
Quantitative prediction of integrase inhibitor resistance from genotype through consensus linear regression modeling.
Van der Borght K et al.
Virology Journal, 2013
HIV-1 integrase sequence variability in antiretroviral naïve patients and in triple-class experienced patients subsequently treated with raltegravir.
Varghese V et al.
Aids Research and Human Retroviruses, 2010
Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1-infected patients, all naive to integrase inhibitors.
Ceccherini-Silberstein F et al.
The Journal of Antimicrobial Chemotherapy, 2010
Secondary integrase resistance mutations found in HIV-1 minority quasispecies in integrase therapy-naive patients have little or no effect on susceptibility to integrase inhibitors.
Ceccherini-Silberstein F et al.
Antimicrobial Agents and Chemotherapy, 2010
Evolution of raltegravir resistance during therapy.
Sichtig N et al.
The Journal of Antimicrobial Chemotherapy, 2009
Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors.
Rhee SY et al.
Retrovirology, 2008
Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance.
Lataillade M et al.
Antiviral Therapy, 2007
Select a paper to view details